Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

Trial Profile

Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2018

At a glance

  • Drugs M 6620 (Primary) ; Veliparib (Primary) ; Cisplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jun 2018 Results (n=23) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 16 May 2018 According to the Merck KGaA media release, data from this trial will be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2018.
    • 28 Oct 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top